

medicina

BUENOS AIRES VOL. 80 Supl. V - 2020



2020

MEDICINA

Volumen 80, Supl. V, Págs. 1-207

medicina

BUENOS AIRES, VOL. 80 Supl. V - 2020

COMITÉ DE REDACCIÓN

Sebastián F. Ameriso
FLENI, Buenos Aires, Argentina

Pablo J. Azurmendi
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Damasia Becú Villalobos
*Instituto de Biología y Medicina Experimental-CONICET,
Buenos Aires, Argentina*

José H. Casabé
*Instituto de Cardiología y Cirugía Cardiovascular,
Hospital Universitario Fundación Favaloro,
Buenos Aires, Argentina*

Hugo N. Catalano
Hospital Alemán, Buenos Aires, Argentina

Eduardo L. De Vito
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Isabel Narvaiz Kantor
Organización Panamericana de la Salud (OPS/OMS) (ret.), Argentina

Basilio A. Kotsias
Instituto de Investigaciones Médicas A. Lanari, UBA, Argentina

Gustavo Kusminsky
Hospital Universitario Austral, Buenos Aires, Argentina

Caroline A. Lamb
*Instituto de Biología y Medicina Experimental (IBYME),
Buenos Aires, Argentina*

Isabel A. Lüthy
*Instituto de Biología y Medicina Experimental (IBYME),
Buenos Aires, Argentina*

Daniel A. Manigot
Hospital San Juan de Dios, Buenos Aires, Argentina

Jorge A. Manni
*Instituto de Investigaciones Médicas A. Lanari,
UBA, Argentina*

Rodolfo S. Martin
*Facultad de Ciencias Biomédicas y
Hospital Universitario Austral, Buenos Aires, Argentina*

Guillermo D. Mazzolini
*Instituto de Investigaciones en Medicina
Traslacional-CONICET,
Hospital Universitario Austral, Buenos Aires, Argentina*

Viviana Ritacco
*Instituto Nacional de Enfermedades Infecciosas
ANLIS-CONICET, Buenos Aires, Argentina*

Guillermo B. Semeniuk
*Instituto de Investigaciones Médicas A. Lanari,
UBA, Argentina*

Oswaldo J. Stringa
Hospital de Clínicas José de San Martín, UBA, Argentina

MIEMBROS EMÉRITOS

Héctor O. Alonso
Instituto Cardiovascular Rosario, Santa Fe, Argentina

María Marta de Elizalde de Bracco
*IMEX-CONICET-Academia Nacional de Medicina,
Buenos Aires, Argentina*

Guillermo Jaim Etcheverry
Facultad de Medicina, UBA, Argentina

Christiane Dosne Pasqualini
Academia Nacional de Medicina, Buenos Aires, Argentina

Rodolfo C. Puche
*Facultad de Ciencias Médicas, Universidad Nacional de Rosario,
Santa Fe, Argentina*

La Tapa (Ver p 5)
Ludueña, 2016
María Luján Álvarez

MEDICINA (Buenos Aires) - Revista bimestral – ISSN 0025-7680 (Impresa) – ISSN 1669-9106 (En línea)

REVISTA BIMESTRAL

Registro de la Propiedad Intelectual N° 02683675
Personería Jurídica N° C-7497

Publicación de la Fundación Revista Medicina (Buenos Aires) Propietario de la publicación: Fundación Revista Medicina
Queda hecho el depósito que establece la Ley 11723

Publicada con el apoyo del Ministerio de Ciencia, Tecnología e Innovación Productiva.

MEDICINA no tiene propósitos comerciales. El objeto de su creación ha sido propender al adelanto de la medicina argentina.

Los beneficios que pudieran obtenerse serán aplicados exclusivamente a este fin.

Aparece en *MEDLINE (PubMed)*, *ISI-THOMSON REUTERS (Journal Citation Report, Current Contents, Biological Abstracts, Biosis, Life Sciences)*, *CABI (Global Health)*, *ELSEVIER (Scopus, Embase, Excerpta Medica)*, *SciELO, LATINDEX, BVS (Biblioteca Virtual en Salud)*, *DOAJ, Google Scholar y Google Books*.

Incluida en el Núcleo Básico de Revistas Científicas Argentinas del CONICET.

Directores Responsables:

Basilio A. Kotsias, Eduardo L. De Vito, Isabel Narvaiz Kantor, Guillermo B. Semeniuk

Secretaría de Redacción: Ethel Di Vita, Instituto de Investigaciones Médicas Alfredo Lanari, Combatientes de Malvinas 3150,
1427 Buenos Aires, Argentina
Tel. 5287-3827 Int. 73919 y 4523-6619
e-mail: revmedbuenosaires@gmail.com – http://: www.medicinabuenosaires.com

Vol. 80, Supl. V, Noviembre 2020

Diagramación y Diseño: Andrés Esteban Zapata - aez.sgi@gmail.com

REUNIÓN DE SOCIEDADES DE BIOCIENCIAS 2020

**LXV REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC)**

**LXVIII REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE INMUNOLOGÍA (SAI)**

**REUNIÓN ANUAL DE LA
SOCIEDAD ARGENTINA DE FISIOLOGÍA (SAFIS)**

10-13 de noviembre de 2020

EDITORES RESPONSABLES

María Cristina Carrillo

Analía Trevani

María Cecilia Larocca

ANNUAL MEETING OF BIOSCIENCE SOCIETIES 2020

**LXV ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC)**

**LXVIII ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE INMUNOLOGÍA (SAI)**

**ANNUAL MEETING OF
SOCIEDAD ARGENTINA DE FISIOLÓGÍA (SAFIS)**

November 10-13, 2020

RESPONSIBLE EDITORS
María Cristina Carrillo
Analía Trevani
Maria Cecilia Larocca

translational apoA-I modifications (probably chronic and progressive) raised a protein conformation with significant loss of function and increased aggregation tendency. Oxidation may help favoring this conformation. The results learnt here strength a close association between amyloidosis and atherosclerosis.

29. (261) COBALT CHLORIDE PROTECTS THE HEART AFTER A GLOBAL ISCHEMIC INSULT.

Gutierrez C¹, Farcy N¹, Bonazzola P¹ y Castilla R¹

¹Universidad de Buenos Aires. CONICET. Instituto Alberto C. Taquini de Investigaciones en Medicina Traslacional (IATIMET)

Introduction: Ischemia-reperfusion (I/R) is one of the main cardiovascular risk factors and leads to heart contractile and energy dysfunction. I/R-induced damage is reduced by ischemic preconditioning. CoCl₂ has properties to function as a preconditioning agent, since it can trigger transcriptional changes that resemble the response to a hypoxic event under normoxic conditions.

Objectives: To evaluate CoCl₂ as a preconditioning therapeutic tool after a myocardial and arterial I/R.

Materials and Methods: Isolated adult Wistar rats hearts were arterially perfused at 37°C by Langendorff method, paced at 3 Hz, exposed to 30 min ischemia followed by 45 min reperfusion (R) in the presence or absence of 0.23 mM CoCl₂ which was maintained or removed after 20 min of R.

Aortic contractility was evaluated in an isolated organ bath trough incubation with cumulative noradrenaline (NA) doses. After NA washing, 20 min of simulated arterial ischemia (SI) and R with or without CoCl₂ was performed, and NA response was re-evaluated.

Results: During R, the presence of CoCl₂ did not alter the cardiac resting pressure, nor the perfusion pressure, but increased the developed pressure (p<0.05) until 20 min which then descend reaching controls values. This decrease was prevented when CoCl₂ was eliminated at 20 min of R. CoCl₂ in R increased the contractile economy (P/Ht) and decreased the cardiac damaged area (p<0.05) and the incidence of arrhythmias (p<0.001).

Post-SI arterial contractility increased at the lowest NA dose but not at higher ones. CoCl₂ in post -SI R did not affect arterial force, but decreased NA sensitivity (EC 50: control: 10^{-7.5}, CoCl₂: 10^{-6.5} M) and the maximum contractile response.

Conclusion: The use of CoCl₂ after an ischemic event attenuates the cardiac damage produced at least during the first 25 min of R and reduces the arterial adrenergic contractile response. These results support the use of CoCl₂ as a potential cardioprotective tool of clinical relevance.

30. (267) H₂O₂, NO AND ONOO⁻ IN THE CARDIAC MITOCHONDRIAL DYSFUNCTION IN A TYPE 1 DIABETES MODEL

Rukavina-Mikusic IA^{1,2}, Rey M¹, Bombicino SS³ and Valdez LB^{1,2}

¹Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Fisicoquímica

²CONICET, Instituto de Bioquímica y Medicina Molecular (IBIMOL; UBA-CONICET), Fisicoquímica

³Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Inmunología e Instituto de Estudios de la Inmunidad Humoral, Prof. Ricardo A. Margni (IDEHU, UBA-CONICET)

AIM: To study the changes of mitochondrial production rates and/or steady-state concentrations ([X]_{ss}) of O₂^{•-}, H₂O₂, NO and ONOO⁻ in the temporal evolution of cardiac mitochondrial dysfunction in a type 1 diabetes model. **METHODS:** Diabetes was induced by a single dose of Streptozotocin (STZ, 60 mg/kg, ip) in male rats. Glycemia (mg/dl) was determined after 72 h (C:130 ± 5; DM:415 ± 23). The animals were sacrificed after 10 or 28 days of STZ-injection (7 or 25 days of hyperglycemia). Mn-SOD activity, and H₂O₂ and NO production rates were determined in the cardiac mitochondrial fraction. [O₂^{•-}]_{ss}, [NO]_{ss} and ONOO⁻ generation were estimated from experimental data. **RESULTS:** When animals were sacrificed 10 days after STZ-injection, heart mitochondrial NO (30%) and H₂O₂ (117%) productions were higher and Mn-SOD activity was lower (15%) than

control values. Moreover, mitochondrial [O₂^{•-}]_{ss} was 2.5-fold higher in heart from diabetic rats, along with a 30% increase in [NO]_{ss}. Thus, ONOO⁻ production rate resulted 3 times higher. When animals were subjected to 25 days of hyperglycemia, Mn-SOD activity was really reduced (50%). While H₂O₂ generation was extremely augmented (128%), the increase in NO generation (23%) was similar to the one observed at 7 days. Increases in [O₂^{•-}]_{ss} (350%), [NO]_{ss} (25%), and ONOO⁻ production (450%) were obtained. Moreover, nitration of tyrosine residues of mitochondrial proteins was observed in diabetic animals sacrificed at day 28. **CONCLUSIONS:** Heart mitochondrial production rates of H₂O₂, NO and ONOO⁻ were higher in diabetic than in control animals, both after 7 and 25 days of hyperglycemia. No difference in the increase -over the control values- of [NO]_{ss} was observed over time, while a much greater rise in [O₂^{•-}]_{ss} was detected after 25 days of sustained hyperglycemia respect to the enhancement obtained at 7 days, intensifying the difference in ONOO⁻ generation. Therefore, ONOO⁻ generation rate is mainly controlled by [O₂^{•-}]_{ss} rather than by [NO]_{ss}.

31. (334) HYPERBARIC OXYGENATION THERAPY IN THE TREATMENT OF COVID-19 (PRELIMINARY REPORT)

Keller GA^{1,2}, Colaianni I¹, Bartolome J¹, Garcia ER¹, Rombola N¹, Cannellotto M³, Di Girolamo G², Di Salvo HE¹.

¹ Hospital General de Agudos Donación Francisco J. Santojanni

² Universidad de Buenos Aires, Facultad de Medicina, Instituto Alberto C. Taquini de investigaciones en Medicina Traslacional (IATIMET).

³ Asociación Argentina de Medicina Hiperbárica e Investigación (AAMHEI)

Introduction: Hyperbaric oxygenation therapy (HBOT) has been shown to reduce the production and release of pro-inflammatory cytokines. Its use in patients with COVID-19 and hypoxemia in China showed promising results although its use was poorly evaluated. **Methods:** A randomized, controlled study was started, comparing standard care (Control Group which includes non-hyperbaric oxygen supply) versus standard care plus HBOT (Test). The HBOT was carried out with Biobarica chambers of national development and medium pressure (1.45 atm) in sessions of 90 minutes per day for at least 5 days. Baseline daily oxygen saturation (SatO2) breathing ambient air (FiO2 = 0.21%) prior to HBOT was recorded. **Results:** 18 patients were included (ratio 1:1). The comparison between the groups did not show significant differences in terms of clinical status, general compromise, laboratory, age, comorbidities or history. The evolution of the HBOT group showed a rapid increase in SatO2 with a significant difference between groups from day 4 onwards. On day 5, the HBOT group presented SatO2 94.4 ± 2.7 (91.0-98.0)% Vs 89.8±2,3 (87,0-94,0) in control group. The time to normalize oxygen Saturation was significantly shorter in the HBOT group [mean±SD (min-max)]: 3,3±1,4 (1,0-5,0) VS 5,8±1,4 (3,0-7,0) days (P=0,002). The ascending slope for SatO2 in HBOT group was significantly higher than the control group: 2,1±0,6 (1,3-3,2) VS 1,5±0,6 (0,8-2,8) %/day (P 0,04). No adverse reactions were recorded. **Discussion:** HBOT shown to be more effective than oxygen supply at ambient pressure. Although the study continues to recruit individuals, initial clinical results show a clear beneficial effect.

Reference: Rui-Yong C et al. Efficacy analysis of hyperbaric oxygen therapy in the treatment of severe coronavirus disease 2019 patients. Acad. J. Second Mil. Med. Univ. ; 6(41): 604-611, 2020.

32. (429) EFFECTS OF REMOTE ISCHEMIC PRECONDITIONING ON EARLY MYOCARDIAL POST-INFARCTION REMODELING

Bin EP¹, Penas F², Goren N², Gelpi RJ¹, Donato M¹

¹ Institute of Cardiovascular Pathophysiology, Faculty of Medicine, University of Buenos Aires

² Institute of biomedical research in retroviruses and AIDS

Introduction: It is known that remote ischemic preconditioning (rIPC) reduces infarct size in experimental models of myocardial infarction (MI); while its effect is controversial in the clinical setting. Particularly, the effect of rIPC on post-infarction ventricular remodel-